319 related articles for article (PubMed ID: 38708177)
21. In perspective: An update on telomere targeting in cancer.
Sugarman ET; Zhang G; Shay JW
Mol Carcinog; 2019 Sep; 58(9):1581-1588. PubMed ID: 31062416
[TBL] [Abstract][Full Text] [Related]
22. Telomere inhibition and telomere disruption as processes for drug targeting.
Rezler EM; Bearss DJ; Hurley LH
Annu Rev Pharmacol Toxicol; 2003; 43():359-79. PubMed ID: 12540745
[TBL] [Abstract][Full Text] [Related]
23. Telomerase inhibitors as anticancer therapy.
Akiyama M; Hideshima T; Munshi NC; Anderson KC
Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):567-75. PubMed ID: 12678724
[TBL] [Abstract][Full Text] [Related]
24. Alternative lengthening of telomeres in cancer stem cells in vivo.
Bojovic B; Booth RE; Jin Y; Zhou X; Crowe DL
Oncogene; 2015 Jan; 34(5):611-20. PubMed ID: 24531712
[TBL] [Abstract][Full Text] [Related]
25. Alternative Lengthening of Telomeres in the Budding Yeast
Cohn M; Andersson AK; Mateo RQ; Möller MC
G3 (Bethesda); 2019 Oct; 9(10):3345-3358. PubMed ID: 31427453
[TBL] [Abstract][Full Text] [Related]
26. Oxidative damage impact on aging and age-related diseases: drug targeting of telomere attrition and dynamic telomerase activity flirting with imidazole-containing dipeptides.
Babizhayev MA; Vishnyakova KS; Yegorov YE
Recent Pat Drug Deliv Formul; 2014; 8(3):163-92. PubMed ID: 24894799
[TBL] [Abstract][Full Text] [Related]
27. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Mueller S; Hartmann U; Mayer F; Balabanov S; Hartmann JT; Brummendorf TH; Bokemeyer C
Invest New Drugs; 2007 Dec; 25(6):519-24. PubMed ID: 17534576
[TBL] [Abstract][Full Text] [Related]
28. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
[TBL] [Abstract][Full Text] [Related]
29. Telomerase Inhibitors from Natural Products and Their Anticancer Potential.
Ganesan K; Xu B
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29267203
[TBL] [Abstract][Full Text] [Related]
30. Alternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells.
Zhao S; Wang F; Liu L
Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31835618
[TBL] [Abstract][Full Text] [Related]
31. Telomerase-Targeted Cancer Immunotherapy.
Mizukoshi E; Kaneko S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013796
[TBL] [Abstract][Full Text] [Related]
32. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
Barszczyk M; Buczkowicz P; Castelo-Branco P; Mack SC; Ramaswamy V; Mangerel J; Agnihotri S; Remke M; Golbourn B; Pajovic S; Elizabeth C; Yu M; Luu B; Morrison A; Adamski J; Nethery-Brokx K; Li XN; Van Meter T; Dirks PB; Rutka JT; Taylor MD; Tabori U; Hawkins C
Acta Neuropathol; 2014 Dec; 128(6):863-77. PubMed ID: 25120190
[TBL] [Abstract][Full Text] [Related]
33. Telomeres and telomerase: understanding basic structure and potential new therapeutic strategies targeting it in the treatment of cancer.
Sekhri K
J Postgrad Med; 2014; 60(3):303-8. PubMed ID: 25121374
[TBL] [Abstract][Full Text] [Related]
34. Telomerase inhibitors for the treatment of cancer: the current perspective.
Perry PJ; Arnold JR; Jenkins TC
Expert Opin Investig Drugs; 2001 Dec; 10(12):2141-56. PubMed ID: 11772310
[TBL] [Abstract][Full Text] [Related]
35. Telomerase inhibition as an adjuvant anticancer therapy: it is more than just a waiting game.
Elmore LW; Holt SE
Expert Opin Ther Targets; 2007 Apr; 11(4):427-30. PubMed ID: 17373872
[TBL] [Abstract][Full Text] [Related]
36. Telomere biology of pediatric cancer.
Tabori U; Dome JS
Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
[TBL] [Abstract][Full Text] [Related]
37. Targeting telomeres and telomerase.
De Cian A; Lacroix L; Douarre C; Temime-Smaali N; Trentesaux C; Riou JF; Mergny JL
Biochimie; 2008 Jan; 90(1):131-55. PubMed ID: 17822826
[TBL] [Abstract][Full Text] [Related]
38. Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase-negative cells.
Zencir S; Hsieh MH; Hsu JS; Ergun Y; Chou GL; Li TK; Teng SC; Topcu Z
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1671-1676. PubMed ID: 32333143
[TBL] [Abstract][Full Text] [Related]
39. MST-312 Alters Telomere Dynamics, Gene Expression Profiles and Growth in Human Breast Cancer Cells.
Gurung RL; Lim SN; Low GK; Hande MP
J Nutrigenet Nutrigenomics; 2014; 7(4-6):283-98. PubMed ID: 26022559
[TBL] [Abstract][Full Text] [Related]
40. Telomeres as targets for anticancer therapies.
Folini M; Venturini L; Cimino-Reale G; Zaffaroni N
Expert Opin Ther Targets; 2011 May; 15(5):579-93. PubMed ID: 21288186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
